logo

Press Releases

    • 19 JAN 2016

    PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes

    SILVER SPRING, Md., Jan. 19, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today another in a series of educational articles that will serve to educate the public on its live-cell encapsulation technology

    Read more →
    • 14 JAN 2016

    PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial

    SILVER SPRING, Md., Jan. 14, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the

    Read more →
    • 07 JAN 2016

    PharmaCyte Biotech to Attend J.P. Morgan Healthcare Conference

    SILVER SPRING, Md., Jan. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s Chief Executive Officer, Kenneth L. Waggoner, will attend the 34th Annual J.P. Morgan Healthcare Conference in San

    Read more →
    • 04 JAN 2016

    PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial

    SILVER SPRING, Md., Jan. 04, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United

    Read more →
    • 30 DEC 2015

    PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs

    SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the

    Read more →
    • 15 DEC 2015

    PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program

    SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media

    Read more →
    • 07 DEC 2015

    PharmaCyte Biotech Provides Update on Malignant Ascites and New Colon Cancer Studies

    SILVER SPRING, Md., Dec. 07, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued an update on the preclinical studies that are designed to determine the effectiveness of the Cell-in-a-Box® plus ifosfamide therapy

    Read more →
    • 04 DEC 2015

    PharmaCyte Contractor Chamow & Associates to Visit Cell-in-a-Box® Encapsulation Facility in Bangkok, Thailand

    SILVER SPRING, Md., Dec. 04, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that representatives from Chamow & Associates, the San Francisco Bay Area firm contracted to assist PharmaCyte in preparing the

    Read more →
    • 24 NOV 2015

    PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment

    SILVER SPRING, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the European Commission has updated its website to reflect that PharmaCyte Biotech Europe Limited, a subsidiary of PharmaCyte

    Read more →
    • 19 NOV 2015

    PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board

    SILVER SPRING, MD, November 19, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte’s Scientific Advisory Board. Prof. Hammes is recognized

    Read more →